How GLP-1 Weight-Loss Drugs Are Rewriting the Rules of the Fragrance Industry
Perfume makers are investigating how GLP-1 drugs like Wegovy influence scent preferences, as users spend 26% more on fragrances to replace food cravings.
POLICY WIRE — New York, USA — The perfume industry is closely monitoring the rise of GLP-1 weight-loss medications, as manufacturers investigate whether drugs like Wegovy and Mounjaro are fundamentally altering consumer fragrance preferences.
Recent data from market researcher NIQ reveals that individuals using GLP-1 therapies spend 26% more on fragrances than the average consumer. Industry experts suggest this trend may stem from a desire to seek sensory pleasure through scent as appetite for food diminishes.
Major fragrance and flavor firms, including Givaudan, IFF, CPL Aromas, and L’Oreal, have confirmed they are studying the potential link between these medications and shifting olfactory tastes. While researchers emphasize that more study is required, some suggest that GLP-1 drugs may impact the olfactory bulb, potentially changing how users perceive and enjoy specific aromas.
Paule Joseph, co-director of the National Smell and Taste Center at the US National Institutes of Health, noted that the idea of these drugs having a chemosensory effect is not a far-fetched idea. Meanwhile, L’Oreal Paris’ Global Brand President Laetitia Toupet observed that users appear to be compensating for the lost pleasure of food with other forms of enjoyment, such as luxury scents.
This shift is fueling a massive expansion in the gourmand fragrance category, which has grown to represent 24% of product innovation, up from 9% just two years ago. Perfumers are moving beyond traditional sweet notes to incorporate complex, edible aromas like banoffee pie, sesame, miso, and even tabasco.
Arnaud Guggenbuhl, global head of marketing for fine fragrance at Givaudan, noted that the company is now creating scents that replicate the layered experience of cakes, including milky and creamy textures. As the market for weight-loss drugs is projected to reach $150 billion by 2030, manufacturers remain committed to capturing the interest of this growing demographic.
Reporting by Policy-Wire (PW)
